Diabetes-related quality of life in six European countries measured with the DOQ-30.
Type 2 diabetes (T2DM)
diabetes-related quality of life (DR-QoL)
patients with diabetes (PWD)
the Diabetes Obstacles Questionnaire-30 (DOQ-30)
Journal
The European journal of general practice
ISSN: 1751-1402
Titre abrégé: Eur J Gen Pract
Pays: England
ID NLM: 9513566
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
entrez:
2
8
2021
pubmed:
3
8
2021
medline:
26
10
2021
Statut:
ppublish
Résumé
The quantification of diabetes-related quality of life (DR-QoL) is an essential step in making Type 2 Diabetes (T2DM) self-management arrangements. The European General Practitioners Research Network (EGPRN) initiated the EUROBSTACLE study to develop a broadly conceptualised DR-QoL instrument for diverse cultural and ethnic groups; high and low-income countries. In 2016 the Diabetes Obstacles Questionnaire-30 (DOQ-30) was introduced. The research aimed to study obstacles a patient with diabetes (PWD) may face in everyday life. First, we assessed how descriptive and clinical characteristics and the residential country were associated with the obstacles. Secondly, we calculated the proportion of respondents who expressed obstacles. Data were collected in 2009 in a cross-sectional survey in Belgium, France, Estonia, Serbia, Slovenia, and Turkey. Multiple linear regressions were computed to detect associations between descriptive and clinical characteristics, residential country, and obstacles. Percentages of respondents who perceived obstacles were calculated. We found that although descriptive and clinical characteristics varied to quite a great extent, they were weakly associated with the perception of obstacles. The residential country was most often associated with the existence of some obstacle. The highest percent (48%) of all respondents perceived 'Uncertainty about Insulin Use' as an obstacle. Descriptive and clinical characteristics were weakly associated with perceived obstacles. However, the residential country plays an essential role in the decline of the QoL of PWDs. Education of both PWDs and healthcare professionals (HCPs) plays an essential role in countering the fear of insulin.
Sections du résumé
BACKGROUND
BACKGROUND
The quantification of diabetes-related quality of life (DR-QoL) is an essential step in making Type 2 Diabetes (T2DM) self-management arrangements. The European General Practitioners Research Network (EGPRN) initiated the EUROBSTACLE study to develop a broadly conceptualised DR-QoL instrument for diverse cultural and ethnic groups; high and low-income countries. In 2016 the Diabetes Obstacles Questionnaire-30 (DOQ-30) was introduced.
OBJECTIVES
OBJECTIVE
The research aimed to study obstacles a patient with diabetes (PWD) may face in everyday life. First, we assessed how descriptive and clinical characteristics and the residential country were associated with the obstacles. Secondly, we calculated the proportion of respondents who expressed obstacles.
METHODS
METHODS
Data were collected in 2009 in a cross-sectional survey in Belgium, France, Estonia, Serbia, Slovenia, and Turkey. Multiple linear regressions were computed to detect associations between descriptive and clinical characteristics, residential country, and obstacles. Percentages of respondents who perceived obstacles were calculated.
RESULTS
RESULTS
We found that although descriptive and clinical characteristics varied to quite a great extent, they were weakly associated with the perception of obstacles. The residential country was most often associated with the existence of some obstacle. The highest percent (48%) of all respondents perceived 'Uncertainty about Insulin Use' as an obstacle.
CONCLUSION
CONCLUSIONS
Descriptive and clinical characteristics were weakly associated with perceived obstacles. However, the residential country plays an essential role in the decline of the QoL of PWDs. Education of both PWDs and healthcare professionals (HCPs) plays an essential role in countering the fear of insulin.
Identifiants
pubmed: 34338125
doi: 10.1080/13814788.2021.1954615
pmc: PMC8330755
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-197Références
Health Qual Life Outcomes. 2013 Oct 16;11:170
pubmed: 24131673
Prim Care Diabetes. 2009 Feb;3(1):43-7
pubmed: 19264569
PLoS One. 2016 Aug 15;11(8):e0160809
pubmed: 27526176
Intern Med. 2013;52(2):179-85
pubmed: 23318846
Turk J Med Sci. 2017 Apr 18;47(2):447-454
pubmed: 28425230
Diabet Med. 2007 Aug;24(8):878-82
pubmed: 17490425
Stat Med. 1998 Apr 30;17(8):857-72
pubmed: 9595616
Diabetes Care. 2012 Nov;35(11):2128-32
pubmed: 22837364
Health Qual Life Outcomes. 2017 Feb 21;15(1):41
pubmed: 28222781
Diabetes Obes Metab. 2012 Dec;14(12):1081-7
pubmed: 22726104
Eur J Gen Pract. 2016;22(1):16-22
pubmed: 26578192
Exp Clin Endocrinol Diabetes. 2018 Jan;126(1):53-60
pubmed: 28704857
Prim Care Diabetes. 2016 Feb;10(1):83-6
pubmed: 25890864
Clin Diabetes. 2015 Jan;33(1):32-6
pubmed: 25653471
Diabetes Care. 2017 Jan;40(Suppl 1):S6-S10
pubmed: 27979888
Prim Care Diabetes. 2016 Apr;10(2):103-10
pubmed: 26186886
J Diabetes Res. 2016;2016:3192673
pubmed: 27446961
Diabetes Res Clin Pract. 2014 May;104(2):281-7
pubmed: 24636627
Diabet Med. 2015 Jun;32(6):725-37
pubmed: 25440507
J Diabetes. 2015 Nov;7(6):800-8
pubmed: 25349949
Can J Diabetes. 2016 Jun;40(3):234-41
pubmed: 26948024
Prim Care Diabetes. 2007 Feb;1(1):25-33
pubmed: 18632016
Diabet Med. 2002 Apr;19(4):279-84
pubmed: 11942998
Int J Family Med. 2012;2012:842912
pubmed: 23251799
Curr Med Res Opin. 2016;32(4):681-6
pubmed: 26743676
Scand J Public Health. 2015 Mar;43(2):111-6
pubmed: 25512098
Diabetologia. 2010 Dec;53(12):2480-6
pubmed: 20711716
Endocrinol Nutr. 2014 Jan;61(1):18-26
pubmed: 24055176
Front Public Health. 2018 Mar 27;6:81
pubmed: 29637064
Qual Life Res. 2007 Mar;16(2):165-77
pubmed: 17033903
Patient Prefer Adherence. 2015 Feb 12;9:289-97
pubmed: 25709415
Diabet Med. 2008 Sep;25(9):1096-101
pubmed: 19183314
Diabet Med. 2016 Sep;33(9):1194-203
pubmed: 27353119